Boston, Massachusetts, March 26, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, […]

Boston, Massachusetts, January 29, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, […]

Supporting Dewpoint’s novel condensate modulating approach to drug previously ‘undruggable’ therapeutic targets, guided by ConcertAI’s Clinico-Genomic Solutions  Boston, MA and […]

BOSTON, Massachusetts, December 4, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today […]

The Pharma Letter features a major milestone for Dewpoint Therapeutics – the nomination of our first development candidate, DPTX3186, as a […]

BOSTON, Massachusetts, October 28, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today the […]

Berlin, Germany and Boston, Mass., USA, October 24, 2024 – Bayer has entered into an exclusive licensing agreement with Dewpoint […]

The Pharma Letter features a Dewpoint Therapeutics company profile, discussing our revolutionary condensate science with broad applicability across therapeutic areas, AI-powered […]

BOSTON, Massachusetts, August 26, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today that […]

BOSTON, Massachusetts, June 25, 2024 – Just over a year after the start of its collaboration, Dewpoint Therapeutics and Novo Nordisk have […]

In June 2024, Lis Leiderman, M.D., MBA joined Dewpoint’s Executive Leadership Team as Chief Financial and Corporate Development Officer. With […]

At Dewpoint, we are working to unlock the full potential of condensate science to discover and develop life-changing treatments for […]

At Dewpoint we are embracing all forms of science from biology, chemistry and physics to data science and artificial intelligence […]

“I believe we are on our way towards a MYC c-mod, says Bede Portz, Dewpoint’s ovarian cancer program lead. Our […]